InsidersTradesSigma
Total declarations
Companies
▲ Purchases (1 ops.)
▼ Sales (0 ops.)
Insider track record
CEODisclosed buys
1
Disclosed sells
0
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Discover the full record of transactions filed by Bolte Axel, Chairman & CEO. Director active across 2 companies, notably Inozyme Pharma, Inc.. Cumulatively, 9 filings have been logged. Split: 1 buy · 0 sell. Total volume traded: €232k. History available since 24 June 2021. The latest transaction was disclosed on 15 May 2025 (Levée d'options). Regulator: SEC (Form 4). The full history is free.
Declarations9 total
152,823 shares@ US$0.9827.2% of flowCommon StockSEC:0000950170-25-075148:0
22,088 sharesCommon StockSEC:0001104659-23-080679:0
14,588 sharesCommon StockSEC:0001410939-23-000077:0
4,806 shares@ US$2.212.0% of flowCommon StockSEC:0001209191-23-022467:0
3,315 shares@ US$2.281.6% of flowCommon StockSEC:0001209191-22-052023:0
7,500 sharesCommon StockSEC:0001410939-22-000069:0
67,750 shares@ US$3.6967.9% of flowCommon StockSEC:0001209191-22-024917:0
Ideal exit: 14 Jan 2023 (T+270)
66,788 shares@ US$0.9816.1% of flowCommon StockSEC:0001209191-21-043205:0
66,788 shares@ US$0.9811.1% of flowCommon StockSEC:0001209191-21-043205
9 of 9 declarations
About Bolte Axel
Axel Bolte is the Chairman & CEO of Inozyme Pharma, Inc. and IVERIC bio, Inc. He leads these companies with a strategic vision focused on innovation and expansion. His leadership is essential for developing therapeutic solutions in the biopharmaceutical sector.
